Editas Medicine, Inc Stock News

Editas (EDIT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CAMBRIDGE, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced that three abstracts have been accepted for presentati

Editas (EDIT) reported earnings 30 days ago. What's next for the stock?

Editas Medicine just successfully navigated a key regulatory issue. Its reni-cel candidate now has a clearer path through its clinical trials.

Editas Medicine has recorded solid progress with its leading candidate. The biotech's financial position looks strong, given its clinical-stage status.

Editas Medicine's fourth-quarter results contained surprises. Financial results were better than expected.

Editas (EDIT) reports better-than-expected fourth-quarter 2023 results as both earnings and revenues beat estimates, driven by collaboration revenues received from Vertex. The stock gains 25%.

Editas Medicine, Inc. (EDIT) Q4 2023 Earnings Call Transcript

Editas Medicine (EDIT) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.52. This compares to loss of $0.88 per share a year ago.

CAMBRIDGE, Mass., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that it will host a conference call and webcast on We

The average of price targets set by Wall Street analysts indicates a potential upside of 80% in Editas (EDIT). While the effectiveness of this highly sought-after metric is questionable, the positive

New drug approvals and pipeline progress are likely to help maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position SRPT, EXEL, IMCR,

Editas Medicine, Inc. (EDIT) Guggenheim 6th Annual Biotechnology Conference (Transcript)

Editas (EDIT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

CAMBRIDGE, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that management will participate in the following upc